| Protein Name: | D(1A) dopamine receptor (P18901) |
|---|---|
| Gene Name: | Drd1 |
| Description: | |
| PDB ID: | |
| Protein Family: | PF00001, PS00237 |
| Protein Category: | Membrane Receptors |
| Protein Name: | D(1A) dopamine receptor (P21728) |
| Gene Name: | DRD1 |
| Description: | D(1A) dopamine receptor |
| PDB ID: | |
| Protein Family: | |
| Protein Category: | Membrane Receptors |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| Gabapentin | Akathisia | Dopamine receptor hypersensitivity hypothesis and the hypothesis of mitochondrial respiratory chain inhibition are evidences for the hypotheses of the pathogenetic mechanisms leading to akathisia(extrapyramidal side effects). [ ADR Type 1 ] | Cell-mediated side effects of psychopharmacological treatment |
| Gabapentin | Dystonic Reactions | Dopamine receptor hypersensitivity hypothesis and the hypothesis of mitochondrial respiratory chain inhibition are evidences for the hypotheses of the pathogenetic mechanisms leading to dystonic reactions(extrapyramidal side effects) [ ADR Type 1 ] | Cell-mediated side effects of psychopharmacological treatment |
| Gabapentin | Parkinsonism | Dopamine receptor hypersensitivity hypothesis and the hypothesis of mitochondrial respiratory chain inhibition are evidences for the hypotheses of the pathogenetic mechanisms leading to parkinsonism(extrapyramidal side effects) [ ADR Type 1 ] | Cell-mediated side effects of psychopharmacological treatment |
| Gabapentin | Tardive Dyskinesias | Dopamine receptor hypersensitivity hypothesis and the hypothesis of mitochondrial respiratory chain inhibition are evidences for the hypotheses of the pathogenetic mechanisms leading to tardive dyskinesias(extrapyramidal side effects). [ ADR Type 1 ] | Cell-mediated side effects of psychopharmacological treatment |
| Haloperidol | Tardive Dyskinesia | HP metabolites bind to the transporters for dopamine and serotonin@which is concerning a possible role of HP metabolites in the development of tardive dyskinesia. [ ADR Type 2 ] | Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia |
| opiates | Hypomotility | Melanotropin release inhibiting factor (MIF) and its analog cyclo(Leu-Gly) (CLG) facilitate dopamine (DA) receptor aGOnist binding and inhibit DA receptor supersensitivity induced by neuroleptics and opiates@which leads to hypomotility [ ADR Type 1 ] | Effect of cyclo(Leu-Gly) on reserpine-induced hypomotility and increases in cortical beta-adrenergic receptors |
This panel provides information on drug category
| Toxicity | Source |
|---|